Skip to Main Content

Author Details

Salvador Fudio
Clinical Development
1998
26
10
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36127823Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Cancer Med2023
37397388A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.Front Oncol2023
36996147Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS.PLoS One2023
34739582Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.Cancer Chemother Pharmacol2022
36029310Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.Cancer Chemother Pharmacol2022
35012962Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.Life Sci Alliance2022
35042701Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.Drug Metab Dispos2022
34453241A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.Invest New Drugs2022
33108504Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.Cancer Chemother Pharmacol2021
33914350Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.J Clin Pharmacol2021
34075384Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.medRxiv2021
30411218First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.Invest New Drugs2019
30090974Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.Clin Pharmacokinet2019
29883879Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine.J Pharm Biomed Anal2018
29974200Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsin.Cancer Chemother Pharmacol2018
27977433Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.Anticancer Drugs2017
28111728Pharmacokinetics and excretion of <sup>14</sup>C-Plitidepsin in patients with advanced cancer.Invest New Drugs2017
28662481Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.J Pharm Biomed Anal2017
21545624Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine.J Clin Pharm Ther2011
19840783Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram.Eur J Pharmacol2010
20925644Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital.Curr Clin Pharmacol2010
19890254A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients.Clin Pharmacol Ther2010
19480891[Valproate-meropenem co-administration, an example of information shortcomings in relevant drug interactions].Med Clin (Barc)2009
18211623Sublingual administration of tacrolimus in a renal transplant patient.J Clin Pharm Ther2008
16882111Epileptic seizures caused by low valproic acid levels from an interaction with meropenem.J Clin Pharm Ther2006
9807854[Cortical processing of visual and auditory stimuli in depressive patients: a study with event related potentials].Actas Luso Esp Neurol Psiquiatr Cienc Afines1998
  • 1 - 26 of 26

Recommended Authors

Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute
Career Start Year 2014
Number of shared co-authors 0
University of Pisa
Career Start Year 2010
Number of shared co-authors 1
University of Toronto
Career Start Year 2010
Number of shared co-authors 0
Drug Metabolism and Pharmacokinetics
Career Start Year 2009
Number of shared co-authors 0
Janssen Research & Development LLC
Career Start Year 2009
Number of shared co-authors 0
Pfizer Inc.
Career Start Year 2008
Number of shared co-authors 0
Federal Institute for Drugs and Medical Devices (BfArM)
Career Start Year 2008
Number of shared co-authors 1
Amunix Pharmaceuticals
Career Start Year 2006
Number of shared co-authors 0
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 1
The Ohio State University
Career Start Year 2005
Number of shared co-authors 1
Unit for Pharmacokinetics and Drug Metabolism, University of Gothenburg
Career Start Year 2005
Number of shared co-authors 0
Stanford University
Career Start Year 2004
Number of shared co-authors 0
Genentech Inc.
Career Start Year 2003
Number of shared co-authors 0
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 1
Sino-French Hoffmann Institute, Guangzhou Medical University
Career Start Year 2003
Number of shared co-authors 1
Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd.
Career Start Year 2002
Number of shared co-authors 2
Harbin Medical University
Career Start Year 2002
Number of shared co-authors 0
Instituto de Investigaciones Biomedicas "Alberto Sols"
Career Start Year 2001
Number of shared co-authors 8
St. Jude Children's Research Hospital
Career Start Year 2001
Number of shared co-authors 0
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 1
and of Biochemistry and Pharmacy, University of Tuebingen
Career Start Year 1996
Number of shared co-authors 1
Ohio State University
Career Start Year 1994
Number of shared co-authors 1
Universite Paris Saclay
Career Start Year 1994
Number of shared co-authors 2
Ohio State University
Career Start Year 1994
Number of shared co-authors 1
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year 1986
Number of shared co-authors 3
University of Kansas Medical Center
Career Start Year 1985
Number of shared co-authors 0
University of Chicago
Career Start Year 1985
Number of shared co-authors 1
Cincinnati Children's Hospital Medical Center
Career Start Year 1982
Number of shared co-authors 0
Center for Precision Medicine and Functional Genomics, Utah Tech University
Career Start Year 1979
Number of shared co-authors 1
Department of Pharmaceutics, University of Florida
Career Start Year 1979
Number of shared co-authors 0

Collaborators

Clinical Development
Co-authored papers 12
Departamento de Toxicologia y Farmacologia Preclinica
Co-authored papers 7
Department of Pharmaceutical Sciences, Utrecht University
Co-authored papers 4
Hospital Universitario Marques de Valdecilla
Co-authored papers 2
Hospital Universitario 12 de Octubre
Co-authored papers 2
Centro Sandoval and Hospital Universitario Clinico de San Carlos
Co-authored papers 2
Hospital Universitario HM Monteprincipe, HM Hospitales
Co-authored papers 2
University College London
Co-authored papers 2
University of the Basque Country UPV/EHU
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 2
Hospital Universitario HM Monteprincipe, HM Hospitales
Co-authored papers 2
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
University of Geneva
Co-authored papers 2
Instituto de Salud Carlos III, Hospital Universitario La Princesa
Co-authored papers 2
Campus Universidad Autonoma de Madrid
Co-authored papers 2
Hospital Germans Trias i Pujol
Co-authored papers 2
Hospital Universitario Quironsalud Madrid
Co-authored papers 2
Clinical R&D
Co-authored papers 2
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 2
Campus Universidad Autonoma de Madrid
Co-authored papers 2
Hospital Universitario de Getafe
Co-authored papers 2
University College London
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
Universidad Europea
Co-authored papers 2
Hospital Universitario de La Princesa
Co-authored papers 2
Co-authored papers 2
Hospital Universitario de Getafe
Co-authored papers 2
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Hospital Universitario Ramon y Cajal
Co-authored papers 2